News

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office.

This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules with similar chemical structures. Specifically, the patent covers methods for treating diseases such as asthma, cancer (including breast and bladder cancer), inflammatory bowel disease, diabetic retinopathy, and other conditions for which antagonism of the adenosine 2B receptor (“A2BR”) offers therapeutic potential.

“This patent provides further protection for our lead molecule, ADO-5030, and our pipeline of best-in-class compounds in the areas of asthma, cancer and other disease indications,” said William Stilley, CEO of Adovate. “It demonstrates Adovate’s leadership in the A2BR space and fortifies Adovate’s dominance in an area of adenosine chemistry we believe is strategic for developing A2BR blockers. It also adds to our patent portfolio, which has patents issuing world-wide.”

Read more here.

Recent News

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …